A Phase II Study of HS-10353 in Participants With Postpartum Depression

NCT05937867 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Postpartum Depression

Interventions

DRUG: HS-10353 Capsules 30 mg, Oral, QN for 14 days
DRUG: HS-10353 Capsules 50 mg, Oral, QN for 14 days
DRUG: HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.
DRUG: HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.